Pedaling at a Low-Moderate Intensity During Chemotherapy Administration

• Status: Enrolling by invitation
• Trial end date: 2021-01-01
• Target enrollment: 20
• Participant gender: All

Summary

The purpose of this study is to evaluate the feasibility of completing a low-moderate intensity pedaling session concurrent to chemotherapy treatment for colorectal cancer. Secondary objectives for this study consist of evaluating the role of pedaling on sarcopenia rates, quality of life markers, chemotherapy side effects, rate of hospital admissions, and treatment delays.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rush University Medical Center

Criteria

Inclusion Criteria:

• Patients with diagnosed colon or rectal cancer with previous surgical intervention and planned intravenous chemotherapy treatment (FOLFOX or FOLFIRI).

• ECOG Performance Status of Grade 0-2.

Exclusion Criteria:

• Limited functional status, demonstrated by an ECOG Performance Status of Grade 3-5.

• Severe cardiac history or comorbidities (i.e. have a cardiac defibrillator or have a history of heart failure, clinically significant aortic stenosis, cardiac arrest, uncontrolled angina, uncontrolled arrhythmias, major heart surgery, stroke, or pulmonary embolus).

• Chest pain or severe shortness of breath at rest or with physical activity.

• Orthopedic impediments to exercise (i.e. joint immobility or lower extremity lymphedema).

• Limitations to sustained exercise (i.e. bone metastases in the femur neck).

• Severe arthritis (i.e. osteoarthritis or rheumatoid arthritis).